Dexcom is maintaining its prior FY26 outlook in view of the current geopolitical realities such as higher oil prices due to Iran’s closure of the Strait of Hormuz in response to the US-Israel’s war ...

Swiss biotech AC Immune discusses its PET tracer's potential in realising precision medicine approaches to neurodegenerative diseases.

The FDA has awarded a breakthrough device designation for Capitan Orthopedics' SupraSpacer implant for patients with irreparable rotator cuff tears.

The funds will advance Axoft’s existing clinical trial programmes and progress US regulatory activities for its implantable brain-computer interface.

GE HealthCare has cut its 2026 growth outlook by 3.3% at the top end, citing increasing freight costs for oil and other materials.

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one day contribute to disease-modifying therapies.

The MUSC and Revival Healthcare Capital have entered a partnership aimed at advancing the clinical development of medical technologies.

VVeno Medical has received the IDE approval from the US FDA for a pivotal study involving a non-surgical replacement venous valve.

According to GlobalData analyst Dr Andrew S Thompson, the deal signals Thermo Fisher’s move away from the IVD space.

Avatar’s software translates CT and MR imaging data into 3D images to streamline surgical planning and operating room workflows.

Tandem has received FDA approval for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type 1 diabetes mellitus.

CareDx’s plans to acquire Naveris follow the divestment of its lab products business earlier this month, reporting flat revenue for the segment in Q1.